Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.72 |
| ▸ | PGK1 | P00558 | 1/20 | 0.69 |
| ▸ | PGK2 | P07205 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanosine SCHEMBL23927999 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL6748957 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8185769 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL4083505 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8612570 | 0.99 | CYP2C19 (0.72) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8612560 | 0.99 | CYP2C19 (0.72) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL3861782 | 0.94 | CYP2C19 (0.67) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL3294897 | 0.94 | CYP2C19 (0.67) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL11084568 | 0.93 | CYP2C19 (0.69) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL3928265 | 0.91 | CYP2C19 (0.62) | CYP2C19SLC29A1ADORA3ADORA1PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 630 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| CN-115474430-A | Composition for treatment and/or prevention of coronavirus infection | 弗劳恩霍夫应用研究促进协会 | 2022-12-13 | — | — | CN | claimed |
| US-20220154222-A1 | NOVEL NUCLEIC ACID MODIFIERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-05-19 | — | — | US | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| WO-2021198440-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2021-10-07 | — | — | WO | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| CN-112552519-A | Preparation method and application of soft metal Au and Cu coordinated sulfur guanosine copolymer | 魏爽 | 2021-03-26 | — | — | CN | claimed |
| EP-3752137-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2020-12-23 | — | — | EP | claimed |
| US-20090042947-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS CONTAINING SULFUR | JON PTY LIMITED (AU) | 2009-02-12 | — | — | US | claimed |
| WO-2008125903-A2 | METHOD OF INHIBITING AN UNDESIRED IMMUNE RESPONSE | CHAIM SHEBA MEDICAL CENTER (US) | 2008-10-23 | — | — | WO | claimed |
| EP-1907407-A1 | IMPROVEMENTS TO ANALOGOUS COMPOUNDS OF 6-THIOGUANOSINE TRIPHOSPHATE, THEIR USE IN MEDICAL FIELDS AND PROCESSES FOR THEIR PREPARATION | Giuliani International Limited (IE) | 2008-04-09 | — | — | EP | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| WO-2007056817-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS CONTAINING SULFUR | JON PTY LIMITED (AU) | 2007-05-24 | — | — | WO | claimed |
| WO-2007010515-A1 | IMPROVEMENTS TO ANALOGOUS COMPOUNDS OF 6-THIOGUANOSINE TRIPHOSPHATE, THEIR USE IN MEDICAL FIELDS AND PROCESSES FOR THEIR PREPARATION | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | CYP2C19 1329/4885SLC29A1 19/4885ADORA3 95/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | CYP2C19 3438/4885SLC29A1 498/4885ADORA3 729/4885 |
| US-20090042947-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS CONTAINING SULFUR | SCLY, STS, SQOR | CYP2C19 263/4885SLC29A1 2579/4885ADORA3 1813/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | CYP2C19 1329/4885SLC29A1 19/4885ADORA3 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.